Show simple item record

dc.contributor.authorSolomon, Scott R
dc.contributor.authorSt Martin, Andrewen_US
dc.contributor.authorZhang, Mei-Jieen_US
dc.contributor.authorBallen, Karenen_US
dc.contributor.authorBashey, Asaden_US
dc.contributor.authorBattiwalla, Minooen_US
dc.contributor.authorBaxter-Lowe, Lee Annen_US
dc.contributor.authorBrunstein, Claudioen_US
dc.contributor.authorChhabra, Saurabhen_US
dc.contributor.authorPerez, Miguel Angel Diazen_US
dc.contributor.authorFuchs, Ephraim Jen_US
dc.contributor.authorGanguly, Siddharthaen_US
dc.contributor.authorHardy, Nancyen_US
dc.contributor.authorHematti, Peimanen_US
dc.contributor.authorMcGuirk, Josephen_US
dc.contributor.authorPeres, Edwarden_US
dc.contributor.authorRingden, Olleen_US
dc.contributor.authorRizzieri, Daviden_US
dc.contributor.authorRomee, Rizwanen_US
dc.contributor.authorSolh, Melhemen_US
dc.contributor.authorSzwajcer, Daviden_US
dc.contributor.authorvan der Poel, Marjoleinen_US
dc.contributor.authorWaller, Edmunden_US
dc.contributor.authorWilliam, Basem Men_US
dc.contributor.authorEapen, Maryen_US
dc.date.accessioned2020-08-14T17:25:42Z
dc.date.available2020-08-14T17:25:42Z
dc.date.issued2020-07-07
dc.identifier.urihttp://hdl.handle.net/10713/13554
dc.description.abstractAlthough hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P =. 51), overall survival (54% versus 57%; P =. 66), or disease-free survival (43% versus 47%; P =. 46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.en_US
dc.description.urihttps://doi.org/10.1016/j.bbmt.2020.06.029en_US
dc.language.isoen_USen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofBiology of Blood and Marrow Transplantationen_US
dc.subjectAfrican Americanen_US
dc.subjectAlternative donoren_US
dc.subjectCaucasianen_US
dc.subjectleukemiaen_US
dc.subjecttransplant-related mortalityen_US
dc.subject.lcshRaceen_US
dc.titleOptimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.bbmt.2020.06.029
dc.identifier.pmid32649981
dc.source.journaltitleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
dc.identifier.eissn1523-6536
dc.source.countryUnited States
dc.identifier.journalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record